home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Dietary Supplements CGMPS - 21 CFR 111 Compliance

 
  January 21, 2019  
     
 
Traininng.com LLC, Online
2019-02-05


Overview

 

21 CFR part 111 ("the DS CGMP rule") requires persons who manufacture, package, label, or hold a dietary supplement to establish and follow current good manufacturing practice-the CGMPs. This is to ensure the quality of the dietary supplement and to ensure that the dietary supplement is packaged and labeled as specified in the master manufacturing record.

This webinar will discuss basic Dietary Supplement CGMP of Part 111 and related requirements, to include:

  • Quality Management System / QA / QC
  • Personnel, Facilities, Equipment
  • Software controls
  • Production and Process Controls
  • Holding and Distribution
  • Complaints and Returns
  • Records

 

Why should you Attend

 

FDA regulates dietary supplements under a different set of regulations than those covering "conventional" foods and drug products. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), Congress defined the term "dietary supplement", and requires that every supplement be labeled a dietary supplement. Beyond that, the industry was only subject to voluntary quality management systems and controls / GMPs, until the Dietary Supplements CGMPs were published as a "final rule" by the FDA, 21 CFR 111, in 2007.

Failure to follow these requirements results in products being termed "adulterated" or "misbranded" by the Agency. There is confusion in the industry as just what type of manufacturing controls and record keeping, and labeling content is required by the FDA, and this confusion continues to cause regulatory problems for many new and established companies in this industry.

 

Areas Covered in the Session

 

  • History of Dietary Supplement regulation in the U.S
  • The Dietary Supplement Health and Education Act (DSHEA)
  • The key requirements of the Dietary Supplements CGMPs, 21 CFR 111
  • Required steps for CGMP compliance
  • Problem areas, common pitfalls
  • Implementation: Systems, templates and tools

 

Who Will Benefit

 

  • Senior Management in Dietary Supplements Industry
  • QA/RA
  • R&D
  • Engineering
  • Marketing
  • Consultants
  • Others Tasked with Product, Process, Validations, CGMP Responsibilities
  • Interested Consumer Groups
  • Medical and Other Healthcare Professionals, Staff and Office Personnel
  • Start-Ups
 
 
Organized by: Traininng.com LLC
Invited Speakers: John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.
 
Deadline for Abstracts: 2019-02-04
 
Registration: https://www.traininng.com/webinar/dietary-supplements-cgmps---21-cfr-111-compliance-200483live?hum-molgen_SEO
E-mail: traininngdotcom@gmail.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.